By 2024, routine testing for genomic alterations has expanded to nine genes with matched targeted therapies for advanced non–small-cell lung cancer (NSCLC) — EGFR, ALK, ROS1, RET, MET, KRAS, NTRK, BRAF, and ERBB2. More than half of patients with NSCLC have genomic alterations in tumor...
Background Osimertinib is a recommended treatment for advanced non鈥搒mall-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant treatment for resected EGFR-mutated NSCLC. EGFR tyrosine kinase inhibitors have shown preliminary efficacy in unresectable stage ...
NSCLCOsimertinibProgrammed death ligand 1EGFR mutated (EGFRm) NSCLC tumors occasionally express programmed cell death ligand 1 (PD-L1), although frequency and clinical relevance are not fully characterized. We report PD-L1 expression in patients with EGFRm advanced NSCLC and association with clinical ...
This subcutaneous administration of Amivantamab covers all current approved or submitted indications of intravenous Amivantamab-vmjw or Rybrevant for patients with EGFR-mutated non-small cell lung cancer or NSCLC. The BLA submission is supported by Phase 3 PALOMA-3 results, which showed a f...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and EGFR-TKI combination treatments have become the standard first-line treatments for EGFR-mutated non-small cell lung cancer (NSCLC) patients. However, the best option has yet to be determined. This study compares the effi...
EGFR-mutated NSCLC is minimally responsive to programmed cell death protein 1 or programmed death-ligand 1 blockade. We evaluated the safety, tolerability, and immunomodulatory effects of the EGFR tyrosine kinase inhibitor (TKI) afatinib in combination with the programmed cell death protein 1 antibody...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent irreversible third-generation EGFR-TKI targeti
[2]P. Janne, D. Planchard, Y. Cheng, et al. FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC. 2023 ESMO. Abstract LBA68. 内容制作 封面图片:摄图网
More and more clinical trials have explored the role of liquid biopsy in the diagnosis and treatment of EGFR-mutated NSCLC. In certain circumstances, liquid biopsy has unique advantages and offers a new way to detect therapeutic targets, analyze drug resistance mechanisms in advanced patients, and ...
Immunotherapy with programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors is considered a promising treatment strategy for NSCLC. However, current evidence suggests that such immunotherapy is not beneficial for patients with NSCLC carrying EGFR mutations. Many preclini...